Aclaris Therapeutics Inc (ACRS)


Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Aclaris Therapeutics Inc chart...

About the Company

aclaris therapeutics, inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. aclaris is focused on market segments with no fda-approved medications or where treatment gaps exist. aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.

CEO

Neal Walker

Exchange

NASDAQ

Website

https://www.aclaristx.com/

$10M

Total Revenue

62

Employees

$88M

Market Capitalization

-0.82

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACRS News

Aclaris Therapeutics: A Year of Financial Resilience and Steady Advancements

25d ago, source: MyChesCo on MSN

WAYNE, PA — Hailed as a leader in kinase discovery and development, Aclaris Therapeutics, Inc. (NASDAQ: ACRS) began 2024 in a ...

Aclaris Therapeutics Inc ACRS

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

1mon ago, source: Stockhouse

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...

Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks

28d ago, source: Business Insider

Aclaris Therapeutics (ACRS) Company Description: Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing ...

Aclaris: Q4 Earnings Snapshot

1mon ago, source: SFGate

WAYNE, Pa. (AP) — WAYNE, Pa. (AP) — Aclaris Therapeutics Inc. (ACRS) on Tuesday reported a loss of $1.5 million in its fourth quarter. The Wayne, Pennsylvania-based company said it had a loss ...

Aclaris Therapeutics Inc earnings beat by $0.33, revenue topped estimates

1mon ago, source: Investing

Investing.com - Aclaris Therapeutics Inc (NASDAQ: ACRS) reported fourth quarter EPS of $-0.02, $0.33 better than the analyst estimate of $-0.35. Revenue for the quarter came in at $17.57M versus the ...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

1mon ago, source: Yahoo Finance

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno ...

Aclaris Therapeutics Inc ACRS

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aclaris Therapeutics Inc

3d ago, source: U.S. News & World Report

Analysts say investors should buy these undervalued stocks.

Aclaris Therapeutics Inc (ACRS)

14d ago, source: Investing

Investing.com - Aclaris Therapeutics Inc (NASDAQ: ACRS) reported third quarter EPS of $-0.41, $0.07 better than the analyst estimate of $-0.48. Revenue for the quarter came in at ...

Aclaris Therapeutics Inc (ACRS)

23d ago, source: Investing

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...